Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Vimian Group AB ( (SE:VIMIAN) ).
Vimian Group AB announced an increase in the number of shares and votes due to the exercise of warrants and conversion of class C shares into ordinary shares. This change reflects the company’s strategic financial adjustments and may impact its market positioning by enhancing shareholder value and voting power distribution.
The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian is a global animal health company that operates in four key areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company is dedicated to providing innovative care solutions for animals, reaching over 17,000 veterinary clinics and laboratories across more than 80 markets. Headquartered in Stockholm, Sweden, Vimian employs 1,200 people and generates annual revenues of approximately EUR 375 million.
Average Trading Volume: 533,725
Technical Sentiment Signal: Sell
Current Market Cap: SEK18.06B
Learn more about VIMIAN stock on TipRanks’ Stock Analysis page.